Skip to main content

Table 2 Results for health-related quality of life from the QLQ-C30

From: Comparing the effectiveness of capecitabine versus 5-fluorouracil/leucovorin therapy for elderly Taiwanese stage III colorectal cancer patients based on quality-of-life measures (QLQ-C30 and QLQ-CR38) and a new cost assessment tool

Dimensions

Capecitabine-based

5-FU/LV-based

P valueb

n

Mean

SD

P valuea

n

Mean

SD

P valuea

Physical

         
 

Baseline

81

73.90

11.78

 

27

80.12

12.46

 

0.746

 

28th week

81

86.14

11.13

<0.0001

27

86.12

11.48

0.038

0.657

Role

         
 

Baseline

81

78.58

11.65

 

27

77.48

14.78

 

0.865

 

28th week

81

90.97

11.08

<0.0001

27

86.77

14.31

0.001

0.582

Emotional

         
 

Baseline

81

84.45

8.54

 

27

83.88

7.57

 

0.537

 

28th week

81

90.24

7.56

<0.0001

27

89.93

6.10

<0.0001

0.357

Cognitive

         
 

Baseline

81

88.18

7.42

 

27

88.58

8.30

 

0.091

 

28th week

81

92.55

7.29

<0.0001

27

87.77

6.93

0.641

0.331

Social

         
 

Baseline

81

83.15

8.58

 

27

82.75

11.85

 

0.313

 

28th week

81

84.86

9.06

0.226

27

91.03

8.98

0.002

0.532

Global health status

         
 

Baseline

81

62.93

6.59

 

27

59.61

8.98

 

0.517

 

28th week

81

75.58

5.64

<0.0001

27

74.76

4.97

<0.0001

0.854

Fatigue

         
 

Baseline

81

25.11

10.49

 

27

25.80

8.81

 

0.884

 

28th week

81

9.34

10.53

<0.0001

27

17.59

9.63

0.002

0.259

Nausea and Vomiting

         
 

Baseline

81

3.91

9.41

 

27

6.77

10.74

 

0.467

 

28th week

81

6.56

9.96

0.002

27

6.81

10.89

0.982

0.187

Pain

         
 

Baseline

81

11.75

8.36

 

27

8.41

7.61

 

0.421

 

28th week

81

4.63

6.24

<0.0001

27

4.07

6.13

0.058

0.746

Dyspnea

         
 

Baseline

81

8.82

8.62

 

27

6.00

9.61

 

0.087

 

28th week

81

6.64

5.13

0.029

27

4.90

8.52

0.536

0.689

Insomnia

         
 

Baseline

81

22.16

15.78

 

27

18.50

13.71

 

0.050

 

28th week

81

16.15

11.96

0.002

27

17.19

11.73

0.603

0.382

Appetite loss

         
 

Baseline

81

10.44

10.91

 

27

19.64

12.17

 

0.004

 

28th week

81

11.10

14.75

0.696

27

11.67

16.08

0.006

0.476

Constipation

         
 

Baseline

81

14.31

12.40

 

27

6.36

11.67

 

0.057

 

28th week

81

14.28

7.64

0.982

27

6.24

6.53

0.951

0.273

Diarrhea

         
 

Baseline

81

13.88

16.39

 

27

13.82

14.39

 

0.581

 

28th week

81

9.05

14.78

0.002

27

12.91

13.16

0.783

0.276

Financial difficulties

         
 

Baseline

81

6.06

6.70

 

27

7.45

7.24

 

0.666

 

28th week

81

6.05

10.20

0.990

27

4.83

10.33

0.118

0.040

  1. a Paired t-test was used to calculate the statistical significance at the 5 % level between the adjusted means at baseline and the 28th week
  2. b Mixed model was used to calculate the statistical significance at the 5 % level following adjustment for patient age, gender, education, marital status, work status, tumor site, family history, comorbidities, use of oxaliplatin, and baseline HRQoL score